New Findings in Hematology: Independent Conference Coverage

Slides:



Advertisements
Similar presentations
IMAJEM, a Substudy of IFM 2009: Prognostic Role of MRI and PET/CT in MM New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December.
Advertisements

Value of MRD to Predict PFS in MM: Results From IFM/DFCI 2009
Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM New Findings in Hematology: Independent Conference Coverage* of ASH.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida First-in-Human Trial: BCMA- Targeted CAR.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
CCO Independent Conference Coverage
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida TOURMALINE-MM1: Improved PFS With Ixazomib.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida Venetoclax + Decitabine or Azacitidine in.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
GALLIUM: Obinutuzumab- vs Rituximab-Based Immunochemotherapy in Patients With Untreated Follicular Lymphoma New Findings in Hematology: Independent Conference.
ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL New Findings in Hematology: Independent Conference.
CCO Independent Conference Highlights
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.
IFM Phase II Study: KRd Induction and Consolidation Before Len Maintenance Highly Effective in Newly Diagnosed MM New Findings in Hematology: Independent.
Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.
CCO Independent Conference Coverage
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
PYRAMID: Frontline R-CHOP ± Bortezomib in Non-GCB DLBCL
CCO Independent Conference Highlights
CCO Independent Conference Highlights
CCO Independent Conference Highlights
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
CCO Independent Conference Highlights
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
CCO Independent Conference Highlights
CCO Independent Conference Highlights
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
CCO Independent Conference Highlights
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
REMARC: Lenalidomide vs Placebo as Maintenance Therapy in Patients With DLBCL Following R-CHOP Induction New Findings in Hematology: Independent Conference.
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
ASSIST-FL: Rituximab Biosimilar GP2013 vs Rituximab in Treatment-Naive Patients With Advanced Follicular Lymphoma New Findings in Hematology: Independent.
FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
CCO Independent Conference Highlights
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.
New Findings in Hematology: Independent Conference Coverage
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
CCO Independent Conference Highlights
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera New Findings in Hematology: Independent Conference Coverage of.
New Findings in Hematology: Independent Conference Coverage
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
Phase Ib MMY1001: Daratumumab Plus Pom/Dex for Patients With R/R MM
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1  
Rigosertib + Azacitidine in Patients With Higher-Risk MDS
New Findings in Hematology: Independent Conference Coverage
Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis New Findings in Hematology: Independent Conference Coverage.
Combination Ruxolitinib + Sonidegib in Myelofibrosis
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.
New Findings in Hematology: Independent Conference Coverage
Presentation transcript:

MPNSG-0212: Ruxolitinib + Pomalidomide Clinically Active and Well Tolerated in MF New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. MF, myelofibrosis. This program is supported by educational grants from Amgen, Celgene Corporation, Merck, Incyte, Seattle Genetics, and Takeda Oncology.

MPNSG-0212: Background Ruxolitinib treats splenomegaly and constitutional symptoms in MF Limited treatment options for cytopenia in MF Pomalidomide may improve anemia and thrombocytopenia in some MF pts[1] MPNSG-0109 trial reports superior efficacy of 2-mg dose of pomalidomide monotherapy vs 0.5 mg QD[2,3] MPNSG-0212 trial evaluates combination of ruxolitinib and pomalidomide to evaluate potential synergy in pts with MF[4] Current analysis reports on first 28 pts[3] MF, myelofibrosis. 1. Tefferi A, et al. J Clin Oncol. 2009;27:4563-4569. 2. ClinicalTrials.gov. NCT00949364. 3. Stegelmann F, et al. ASH 2015. Abstract 826. 4. ClinicalTrials.gov. NCT01644110. Slide credit: clinicaloptions.com

MPNSG-0212: Study Design Open-label, single-arm, multicenter phase Ib/II trial 2-stage design: extend recruitment if response achieved in ≥ 12/37 pts Primary endpoint: RR after 12 cycles per IWG-MRT criteria, transfusion independence Secondary endpoints: PFS, DOR, OS, QoL, and safety Adults with untreated or pretreated primary or secondary MF with anemia, platelets > 100/nL (N = 28) Pomalidomide 0.5 mg PO QD + Ruxolitinib 10 mg* PO BID 28-day cycles 12 cycles planned with extension considered; safety, efficacy evaluated every 28 days *Initial dose; modifications allowed to optimize efficacy, manage myelosuppression DOR, duration of response; MF, myelofibrosis; QoL, quality of life; RR, response rate. Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826.

MPNSG-0212: Baseline Characteristics Ruxolitinib + Pomalidomide (N = 28) Median age, yrs (range) 74 (49-81) Pretreated, n (%) 13 (46) Median spleen size by ultrasound, cm (range) 17.5 (12.6-28) Median hemoglobin, g/dL (range) 8.8 (6.8-11.7) RBC transfusion dependent, n (%) 8 (29) Mutation, n (%) JAK2 V617F MPL W515L CALR 19 (68) 3 (11) 6 (21) DIPSS risk, n (%) Low Intermediate-I Intermediate-II High 1 (4) 2 (7) 20 (71) 5 (18) DIPSS, Dynamic International Prognostic Scoring System; RBC, red blood cell. Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826.

MPNSG-0212: Efficacy At analysis, 16/28 pts (57%) still on treatment 10 (36%) achieved stable disease; median cycles: 9 (2-17) 6 (21%) achieved clinical improvement; median cycles: 12.5 (9-18) Spleen, neutrophil count, hemoglobin, or transfusion independence Of evaluable pts, 14% showed reduction of splenomegaly, 7% cytopenia improvement Median time to response: 5 cycles (2-14) Mean hemoglobin increased from 8.9 g/dL at baseline (N = 28) to 10.2 g/dL at cycle 12 (n = 5) Largest increases post cycle 9 for pts still on treatment Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826.

MPNSG-0212: Mean Hemoglobin Over Time 10.2 10 9.5 9 8.5 8 8.9 Hemoglobin, g/dL [cycle] 1 2 3 4 5 6 7 8 9 10 11 12 n = 28 n = 25 n = 20 n = 13 n = 5 Mean hemoglobin increased from 8.9 g/dL at baseline to 10.2 g/dL at cycle 12 Largest increases post cycle 9 for pts still on treatment Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826. Reproduced with permission.

Ruxolitinib + Pomalidomide MPNSG-0212: Safety Total number of events: 312 13 serious AEs, 3 related to treatment Neuropathy, anemia, and increases in liver enzymes 2 deaths, unknown if related to treatment Cardiac decompensation, septic shock AE Occurring in ≥ 3 Pts, n Ruxolitinib + Pomalidomide (N = 28) Grade 1/2 Grade 3/4 Anemia 3 10 Fatigue Dyspnea 8 Abdominal pain 5 2 Musculoskeletal pain 1 Dizziness Infection Hyperuricemia Renal (peripheral edema) AE, adverse event. Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826.

MPNSG-0212: Conclusions Combination of ruxolitinib and pomalidomide relatively well tolerated and clinically active in a pretreated and high-risk MF pt group Investigators conclude that combination therapy feasible Serious events likely related to drug were manageable 36% of pts had stable disease, some continuing treatment beyond 12 cycles Hematopoietic response seen later than spleen response Interim analysis planned after 37 pts; will consider higher pomalidomide dose to improve anemia response MF, myelofibrosis. Slide credit: clinicaloptions.com Stegelmann F, et al. ASH 2015. Abstract 826.

Go Online for More CCO Coverage of ASH 2015! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in: Acute leukemias/chronic leukemias Myeloma/plasma cell disorders Lymphomas MDS and myeloproliferative neoplasms clinicaloptions.com/oncology